Adding radiotherapy to androgen deprivation therapy improves survival in men with locally advanced prostate cancer, according to the first adequately powered trial on the topic.
At six years follow-up, combination treatment improved cancer specific survival by 10% in absolute terms and by 46% in relative terms compared with ADT alone, the RCT of more than 1200 men with high-risk disease found.
For overall survival, the primary endpoint, the corresponding improvements were 8% and 23% (p=0.003), the phase III study found.
“Our findings suggest that the benefits of the combination of ADT and RT should be discussed with all patients considering a curative treatment approach,” the study authors wrote in the Lancet.
Contrary to previous studies, the authors found side-effects related to radiation were ‘modest...
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.